This anti-inflammatory drug can reduce the risk of a heart attack


FDA proposes reducing nicotine in cigarettes

Health at home
208 points

A hope for the cure of Leukemia: vaccine made with patients own cells

Health at home
274 points

Most recent

The black boy who grew up in Nazi Germany

Amazing histories
222 points

Meet the nun who became a cleaning icon after Hurricane Irma

About everything
52 points

Diabetes can be (and cause) a real headache

Luffy News
118 points

Los arqueólogos descubren marcas de luz sólo visibles a/con la luz de la luna en un monumento/dolmen

Camino y perspectiva
30 points

(sin comentarios)

Camino y perspectiva
24 points


Camino y perspectiva
22 points


I'm Chester O'Brien
22 points

Lo importante no es ganar...

¡Yo Voté NO!
18 points

Say goodbye to tooth cavities, aspirin could be the solution

You have to know
42 points

Tinelli cobró $ 54 millones del gobierno Kirchnerista

40 points
Canakinumab, reduces the danger of a second attack by 15%. This anti-inflammatory drug could reduce the risk of a heart attack.

This anti-inflammatory drug can reduce the risk of a heart attack

The link between inflammation and the formation of plaques in the arteries that can lead to a heart attack has long been observed. A clinical trial of more than 10,000 patients in 40 countries has shown that an anti-inflammatory drug can reduce cardiovascular risk regardless of cholesterol level.

Canakinumab was initially developed against arthritis. The research gave the result: patients treated not only had their arteries clearer, they also had fewer cases of lung cancer than those who received a placebo substance.

Each dose of the drug that Novartis has developed costs $ 16,000 per dose, which is given by intravenous infusion. In addition, there is a 1% chance that this anti-inflammatory drug will produce a fatal infection, especially among elderly patients and diabetes. Physicians should still assess the benefits and risks of treatment.

It is probably decided to book this treatment for the most at risk patients.

To comment you must log in with your account or sign up!
Featured content